How the Medical Device Industry is Shaping Cardiology Innovation

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, with the World Health Organization estimating it to take 17.9 million lives annually. These high figures are sparking a constant demand for innovative diagnosis and treatment technologies. Therefore, companies operating within the medical device industry are under major pressure to continue to innovate and scale their solutions. 

This guide will explore five of the key devices that are driving the identification of diseases and improving the often life-saving care of patients. We will also explore the role of our medical device staffing team in supporting the advancement of cardiology innovation.  

Five Key Medical Device Innovations in Cardiology 

With such concerning figures for the number of deaths globally, here are five key innovations from the medical device industry that are improving treatment and saving the lives of patients worldwide: 

1. Ultromics EchoGo Heart Failure 

Ultromics, a leader in AI-driven cardiology solutions, unveiled its latest improvement to EchoGo Heart Failure in 2025. This is the introduction of a first-of-its-kind AI-powered probability scoring system for the assessment of heart failure with preserved ejection fraction (HFpEF). This advancement marks a groundbreaking development in the use of deep learning to enhance the detection of this often underrecognized condition.  

This new medical device has been rigorously validated in a study at Beth Israel Deaconess Medical Centre (BIDMC) and other leading clinical sites. The study focused on complex, real-world cases, such as patients with multiple overlapping comorbidities, where traditional diagnostics models may not be able to effectively distinguish between cases and controls. Here's what the study found:

• The scoring system provided substantial added information, helping to provide accurate support in the diagnosis of HFpEF, detecting the likelihood of disease, and improving patient outcomes. 
• It demonstrated higher sensitivity in detecting HFpEF and enhanced differentiation between HFpEF and clinically complex controls at risk or with possible HFpEF.
• The patients flagged by the EchoGo heart Failure as high-risk displayed a two-fold increase in the likelihood of heart failure hospitalizations and mortality. This highlights the potential of AI to inform timely interventions that could elevate patient management. 
• Using all available clinical information with the EchoGO Heart Failure saw a 33% improvement in correctly managing patients with HFpEF compared with just relying on the H2FPEF score. 

Ross Upton, PhD, Founder, CEO, and Chief Scientific Officer of Ultromics, commented: 

"The introduction of the probability scoring feature into the EchoGo Heart Failure platform represents a pivotal step forward in heart failure detection and patient risk stratification. By delivering a precise probability score, EchoGo Heart Failure enables clinicians to assess a patient's likelihood of disease, allowing for more confident decision-making".

2. Medtronic Onyx Frontier Drug-eluting Stent (DES)

In 2022, Medtronic announced the launch of the Onyx Frontier Drug-eluting Stent (DES) following its FDA and CE Mark approval. Used in the treatment of patients with Coronary Heart Disease (CAD), it offers an innovative delivery system and builds upon the clinical data and acute performance from the Resolute Onyx DES. It uses the same best-in-class stent platform as Resolute Onyx DES, with an improved delivery system designed to enhance deliverability and increase acute performance in the most challenging of cases. 

What are its key features? 

• It offers design changes, including a lower crossing profile, innovative dual-layer balloon, and increased catheter flexibility, which leads to a 16% improvement in deliverability vs. the Resolute Onyx DES without compromising on radical strength. 
• It also offers a broad-size matrix to treat patients with diameters ranging from 2.0mm to 5.0mm. Its 4.50-5.00mm sizes can be expanded to 6.00mm, specifically designed to support extra-large vessels. 
• It has inherited the same clinical data and indications as Resolute Onyx. This includes approval for bifurcation lesions, left main PCI, and one month of Dual Antiplatelet Therapy (DAPT) in high-bleeding patients. 

Following its launch, Jason Weidman, Senior Vice President at Medtronic, stated: 

‘Following our launch in the United States, we’re thrilled to provide hospitals across western Europe and the globe with the Onyx Frontier DES, which has been thoughtfully designed with physicians’ needs in mind. This launch furthers Medtronic’s goal of engineering the extraordinary, and we look forward to continuing to pursue innovation each day.’

If you would like to explore how our medical device staffing team supported a major company headhunting key roles, including regional sales directors, product management, clinical specialists, and a VP of sales, discover our case study. 

3. Capstan Medical Robotic-Assisted TMVR Platform

In 2025, Capstan Medical declared that the company’s minimally invasive robotic structural heart platform successfully completed the first-in-human robotic-assisted transcatheter mitral valve replacement procedures. The procedures were performed on patients at the Hospital Clinico Universidad Catolica in Chile. 

Key highlights of the procedures include:

• Dr Gonazalo Martinez, MD at the hospital, commented, 'We are honored to pioneer this innovation that has the potential to transform how we treat heart valve disease, especially for patients who aren't candidates for conventional surgery. The Capstan technology exceeded our expectations even in these early cases.'
• The platform provided unprecedented catheter control and stability, helping to achieve optimal implant positioning. 
• Both patients had the elimination of their mitral regurgitation with unobstructed left ventricular outflow tracts.

Capstan has also advised that after closing the $100 million Series C funding, announced in December 2024, it will continue the clinical and development work leading to pivotal trials. The organization is working on developing a suite of next-generation heart valve implants and also a first-of-its-kind kind catheter-based robotic delivery platform. Watch this space and see how Capstan continues to drive innovation far into the future!

4. BiVACOR Total Artificial Heart (TAH)

While current TAH technologies use volume displacement pump designs with flexible polymer diaphragms to pump blood, the BiVACHOR TAH is an electro-mechanical rotary blood pump. The key design innovation lies in its streamlines construction, featuring a single motor and a magnetically levitated rotor that simultaneously pumps blood to both the body and the lungs. Some of its key benefits include: 

• It is capable of providing high flows over L/min. This is enough cardiac output for an adult male doing exercise. 
• Highly durable due to it being constructed from titanium based on its material properties of corrosion resistance, strength, and high biocompatibility. 
• A small external controller paired with a rechargeable battery system enables untethered operation from an AC power source, which helps improve patient mobility and freedom of movement.
• The pump operation is driven by a smart controller that adjusts in real time to changes in patient activity and cardiac output needs. 

In 2025, it was reported that an Australian patient lived for 100 days with the BiVACOR TAH. The ability of the device to sustain the patient for so long is being celebrated as an indication that the device could potentially offer a long-term solution to those suffering from heart failure. BiVACOR's founder, Daniel Timms, commented that it was:

‘Exhilarating to see decades of work come to fruition. The entire BiVACOR team is deeply grateful to the patient and his family for placing their trust in our Total Artificial Heart. Their bravery will pave the way for countless more patients to receive this life-saving technology.”

5. Anteris Technologies DurAVR TAVR System

The DurAVR TAVR system is a transcatheter heart valve (THV) used for treating aortic stenosis. It was the first TAVR to use a single piece of bioengineered tissue. This biomimetic valve is shaped to mimic the performance of a healthy human aortic valve. As of April 2025, it has been used to treat over 100 patients globally, including valve-in-valve (ViV), de novo aortic stenosis, and complex anatomies such as bicuspid aortic valve patients. 

Here are some of its key features: 

• ADAPT Tissue - The DurAVR TAVR is made using ADAPT tissue, which is Anteris’ patented anti-calcification tissue technology. The tissue has been used clinically for over a decade and has been distributed for use in over 55,000 patients globally. 
• ComASUR Delivery System - This was designed to provide accurate placement and controlled deployment of the DurAVR THV with balloon-expandable delivery. This allows for precise alignment with the heart's native commissures in order to achieve optimal valve positioning.

 Dr Michael Reardon, Professor of Cardiothoracic Surgery at Houston Methodist DeBakey Heart and Vascular Center, was full of praise for the device, stating: 

‘A balloon expandable valve with self-expanding hemodynamics is like structural heart holy grail.’

The Role of Medical Device Staffing in Advancing Cardiology

The creation of these medical device innovations is improving the lives of patients worldwide, now and in the future. However, none of these advancements would have been possible without the support of professionals working in areas such as clinical affairs, R&D, sales and business development, engineering, and many more. Therefore, if businesses want to make an impact on the future of cardiology, they need to build teams of industry-leading talent. 

Our medical device staffing team’s vast expertise in the technologies needed to drive improvement in patient care in the cardiology sector means we are well-placed to ensure your business has the skills and expertise it needs to drive the next generation of innovation that could save lives worldwide. Here is an insight into how we can support you:

Deep Expertise and Strong Medical Device Industry Presence

We have a dedicated cardiology staffing team that has built extensive partnerships with non-surgical and surgical cardiovascular device companies. We have built unrivaled expertise and extensive candidate networks in key areas such as electrophysiology, cardiology, hematology, and vascular. 

Global Reach 

We provide contact, executive, and permanent medical device staffing solutions for the cardiology sector across Asia, Europe, and the US. So, whether you are looking for sales professionals to take your products to market or regulatory specialists who will ensure your medical device innovations are compliant, we’ll provide you access to global talent with the expertise you need to scale your business. 

Bespoke Talent Solutions 

Our medical device staffing team is dedicated to providing customized talent solutions to find the niche expertise you need that other agencies often miss. Whatever growth stage you are at, from ambitious startups to multinationals, we develop a close partnership with you to understand your mission and ambitions. We then use our unmatched market intelligence to attract candidates who align with your needs and innovation goals. 

Looking for Expert Medical Device Staffing Solutions? 

To ensure you have the skills and expertise you need to drive innovation in the cardiology sector and make your impact on patient care, our dedicated medical device staffing team is here to support you. 

Get in touch today and see how we can help your business get an edge in your markets.